Report cover image

TRAIL receptor 2 agonists - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 60 Pages
SKU # DEL18680171

Description

TRAIL receptor 2 agonists - Pipeline Insight, 2024



DelveInsight’s, “TRAIL receptor 2 agonists - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in TRAIL receptor 2 agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
TRAIL receptor 2 agonists Understanding

TRAIL receptor 2 agonists: Overview

TRAIL receptor 2 (TRAILR2), also known as Death receptor 5 (DR5), is a cell surface receptor of the TNF-receptor superfamily that binds TRAIL and mediates apoptosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) preferentially induces apoptosis in neoplastic cells upon binding to its receptors TRAIL-R1 and TRAIL-R2. This biological principle has been adopted for the development of cancer-selective therapies. However, many tumor cells are resistant to TRAIL and moreover TRAIL-R1/R2 can activate pro-inflammatory pathways thereby promoting invasion, migration, and metastasis

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence TRAIL receptor 2 agonists R&D. The therapies under development are focused on novel approaches for TRAIL receptor 2 agonists.
TRAIL receptor 2 agonists Emerging Drugs Chapters

This segment of the TRAIL receptor 2 agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TRAIL receptor 2 agonists Emerging Drugs
  • INBRX-109: Inhibrx
INBRX-109 is a tetravalent DR5 agonistic antibody, is designed to exploit tumor-biased direct cell death induction by DR5 activation in numerous cancer types. With a valency of four, it has the ability to potently agonize DR5 through efficient receptor clustering, causing cell death, but by way of our sdAb platform, also eliminates recognition by pre-existing anti-drug antibodies (ADAs) to lessen the potential for hyper-clustering. In January 2021, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma.
  • BI 905711: Travere Therapeutics
BI 905711 is a tetravalent bispecific antibody that cross-links the pro-apoptotic tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAILR2) with the tumor cell anchor cadherin 17 (CDH17). CDH17-dependent clustering of TRAILR2 allows BI 905711 to induce selective apoptosis in CDH17-expressing tumor cells. BI 905711 is currently being investigated in patients with advanced gastrointestinal (GI) cancers.

Further product details are provided in the report……..

TRAIL receptor 2 agonists: Therapeutic Assessment

This segment of the report provides insights about the different TRAIL receptor 2 agonists drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on TRAIL receptor 2 agonists
There are approx. 5+ key companies which are developing the TRAIL receptor 2 agonists. The companies which have their TRAIL receptor 2 agonists drug candidates in the most advanced stage, i.e. Phase II include, Inhibrx.
  • Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
TRAIL receptor 2 agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TRAIL receptor 2 agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TRAIL receptor 2 agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TRAIL receptor 2 agonists drugs.

TRAIL receptor 2 agonists Report Insights
  • TRAIL receptor 2 agonists Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
TRAIL receptor 2 agonists Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing TRAIL receptor 2 agonists drugs?
  • How many TRAIL receptor 2 agonists drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TRAIL receptor 2 agonists?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TRAIL receptor 2 agonists therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for TRAIL receptor 2 agonists and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Inhibrx
  • Boehringer Ingelheim
  • IGM Biosciences
  • Amgen
  • Genmab
  • Theraly Fibrosis
  • IGM Biosciences
Key Products
  • INBRX-109
  • BI 905711
  • IGM 8444
  • Conatumumab
  • Benufutamab
  • TLY 012
  • Anti-DR5 IgM antibody

Table of Contents

60 Pages
Introduction
Executive Summary
TRAIL receptor 2 agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TRAIL receptor 2 agonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
INBRX-109: Inhibrx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BI 905711: Boehringer Ingelheim
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
TLY 012: Theraly Fibrosis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TRAIL receptor 2 agonists Key Companies
TRAIL receptor 2 agonists Key Products
TRAIL receptor 2 agonists- Unmet Needs
TRAIL receptor 2 agonists- Market Drivers and Barriers
TRAIL receptor 2 agonists- Future Perspectives and Conclusion
TRAIL receptor 2 agonists Analyst Views
TRAIL receptor 2 agonists Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us